REGENXBIO INC (RGNX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RGNX • US75901B1070

8.64 USD
-0.21 (-2.37%)
Last: Feb 11, 2026, 12:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, RGNX scores 4 out of 10 in our fundamental rating. RGNX was compared to 523 industry peers in the Biotechnology industry. RGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RGNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year RGNX has reported negative net income.
  • In the past year RGNX has reported a negative cash flow from operations.
  • In the past 5 years RGNX reported 4 times negative net income.
  • RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

  • The Return On Assets of RGNX (-33.88%) is better than 63.67% of its industry peers.
  • RGNX has a Return On Equity (-110.20%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • With an excellent Gross Margin value of 87.18%, RGNX belongs to the best of the industry, outperforming 89.48% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RGNX has declined.
  • RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RGNX has more shares outstanding
  • Compared to 5 years ago, RGNX has more shares outstanding
  • RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -2.28, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
  • RGNX has a Altman-Z score (-2.28) which is in line with its industry peers.
  • There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.28
ROIC/WACCN/A
WACC12.44%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.66 indicates that RGNX has no problem at all paying its short term obligations.
  • The Current ratio of RGNX (2.66) is worse than 68.64% of its industry peers.
  • RGNX has a Quick Ratio of 2.66. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
  • RGNX's Quick ratio of 2.66 is on the low side compared to the rest of the industry. RGNX is outperformed by 66.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.32% over the past year.
  • The Revenue has grown by 91.30% in the past year. This is a very strong growth!
  • Measured over the past years, RGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.81% on average per year.
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%

3.2 Future

  • RGNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.49% yearly.
  • Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 49.19% on average per year.
EPS Next Y30.27%
EPS Next 2Y19.99%
EPS Next 3Y12.93%
EPS Next 5Y16.49%
Revenue Next Year105.8%
Revenue Next 2Y74.13%
Revenue Next 3Y57.31%
Revenue Next 5Y49.19%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RGNX's earnings are expected to grow with 12.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.99%
EPS Next 3Y12.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENXBIO INC

NASDAQ:RGNX (2/11/2026, 12:39:43 PM)

8.64

-0.21 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners83.17%
Inst Owner Change-1.19%
Ins Owners7.13%
Ins Owner Change15.4%
Market Cap437.36M
Revenue(TTM)161.32M
Net Income(TTM)-177.91M
Analysts84.21
Price Target33.35 (286%)
Short Float %11.01%
Short Ratio6.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.56%
Min EPS beat(2)-22.99%
Max EPS beat(2)9.88%
EPS beat(4)2
Avg EPS beat(4)-18.77%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.87%
EPS beat(12)5
Avg EPS beat(12)-7.23%
EPS beat(16)6
Avg EPS beat(16)-6.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.34%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-7.89%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-13.33%
Revenue beat(12)3
Avg Revenue beat(12)-16.53%
Revenue beat(16)5
Avg Revenue beat(16)-11.02%
PT rev (1m)1.67%
PT rev (3m)4.68%
EPS NQ rev (1m)-8.76%
EPS NQ rev (3m)-196.26%
EPS NY rev (1m)-2.92%
EPS NY rev (3m)-23.06%
Revenue NQ rev (1m)-4.96%
Revenue NQ rev (3m)-42.77%
Revenue NY rev (1m)-1.82%
Revenue NY rev (3m)-23.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.71
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS3.19
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.18%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.93%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -2.28
F-Score5
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
EPS Next Y30.27%
EPS Next 2Y19.99%
EPS Next 3Y12.93%
EPS Next 5Y16.49%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%
Revenue Next Year105.8%
Revenue Next 2Y74.13%
Revenue Next 3Y57.31%
Revenue Next 5Y49.19%
EBIT growth 1Y36.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.09%
EBIT Next 3Y23.42%
EBIT Next 5Y19.27%
FCF growth 1Y54.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.4%
OCF growth 3YN/A
OCF growth 5YN/A

REGENXBIO INC / RGNX FAQ

What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to RGNX.


What is the valuation status for RGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.


Can you provide the profitability details for REGENXBIO INC?

REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.


What is the financial health of REGENXBIO INC (RGNX) stock?

The financial health rating of REGENXBIO INC (RGNX) is 6 / 10.